Citations

Clear

88 citation(s) found for "Stan, Marius".

SAT-424 Assessing Content Validity of the Graves’ Ophthalmopathy Quality of Life Questionnaire (GO-QOL) in the United States
Holt, Robert J. , Sile, Saba, Stan, Marius N. , Padnick‐Silver, Lissa

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.1536 Get It

Abstract Introduction: Thyroid eye disease (TED) is an autoimmune condition that negatively impacts patient’s quality of life (QOL). The GO-QOL questionnaire was originally developed in the Netherlands to quantify how TED and treatments affect patient QOL. This questionnaire includes eight questions each on visual functioning and appearance related QOL; the items are answered on a 3-point Likert scale and transformed to a 0 (worst) to 100 (best) scale. Though widely used and validated outside the US, the questionnaire has not been validated in the United States (US). Here we examine the content validity. Methods: Patients with moderate or severe TED were identified using an existing market research patient database, clinician referrals, patient groups, and social media. Interested participants were screened for eligibility prior to completing the GO-QOL. Subjects were also questioned about TED-related signs, symptoms, and treatments and underwent a cognitive interview following GO-QOL completion. Results: Thirteen TED patients completed the assessments (mean age = 44.8 ± 11.5 years, range: 26-67); all were female. Mean TED duration was 4.6 ± 5.5 years (range: 0.4-20.7). Twelve patients (92.3%) had Graves’ disease and one had Hashimoto’s thyroiditis. Descriptions of how TED signs and symptoms impacted quality of life were consistent with GO-QOL items, and qualitative interviews indicated that patients found the GO-QOL content relevant and complete. Responses indicated that minor wording changes may be needed to account for US cultural and language conventions and prevent confusion (specifically related to a bicycling question [12/13 reported not regularly riding a bike before TED symptom onset]). Visual functioning impacts most commonly-reported during the interview were difficulty driving a motor vehicle (92% of participants), difficulty with electronic screens (e.g., televisions, smart phones, and computers; 77%), difficulty moving around outdoors (including issues with light sensitivity, uneven surfaces, and depth perception; 69%), and difficulty doing hobbies or pastimes (69%). Emotional/psychological impacts frequently reported by participants were change in appearance (92%), depression and anxiety (including fear and worry; 77%), and frustration and anger (including moodiness; 69%). Negative reactions from others (staring, asking questions), social impacts and isolation, and lack of self-confidence and embarrassment were also reported (each 62%). Conclusion: This analysis of US patient interviews offered strong support for GO-QOL content validity. Therefore, the GO-QOL is appropriate to quantify TED-related QOL impact in a US population. However, a few slight wording modifications may be needed for future optimal use in the US.Reference: Terwee CB. Br J Ophthalmol 1998;82:773-779
Teprotumumab Significantly Improves Active Moderate-to-Severe Thyroid Eye Disease
Banga, J. Paul, Stan, Marius N.

Mayo Clinic

Clinical Thyroidology | March 9, 2020 | Volume: 32 | Issue: 3 | Pages: 114-116

10.1089/ct.2020;32.114-116 Get It

Steroids Are Effective for Preventing Post-RAI Graves’ Orbitopathy In Those with Graves’ Disease of
Kahaly, George J. , Stan, Marius N.

Mayo Clinic

Clinical Thyroidology | February 7, 2020 | Volume: 32 | Issue: 2 | Pages: 62-64

10.1089/ct.2020;32.62-64 Get It

Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study
Brito, Juan P. , Payne, Stephanie , Ospina, Naykky Singh , Rodríguez‐Gutiérrez, René , Maraka, Spyridoula , Sangaralingham, Lindsey R. , Iñiguez‐Ariza, Nicole M. , Stan, Marius N. , Singh Ospina, Naykky, Maraka, Spyridoula , Stan, Marius N , Singh Ospina, Naykky , Brito, Juan P , Montori, Víctor M.

Mayo Clinic

Thyroid | January 24, 2020 | Volume: 30 | Issue: 3 | Pages: 357-364

10.1089/thy.2019.0132 | PMID 31973681 Get It

Alemtuzumab, an Immunomodulatory Agent for Multiple Sclerosis, Frequently Induces Thyroid Autoimmunity
Stan, Marius N. , Brito, Juan P.

Mayo Clinic

Clinical Thyroidology | November 7, 2019 | Volume: 31 | Issue: 11 | Pages: 467-469

10.1089/ct.2019;31.467-469 Get It

The Levothyroxine Absorption Test: A Four-Year Experience (2015–2018) at The Mayo Clinic
Gonzales, Kristen , Stan, Marius N. , Bernet, Victor , Castro, M. Regina , Gonzales, Kristen M, Stan, Marius N , Morris, John C.

Mayo Clinic

Thyroid® | November 2, 2019 | Volume: 29 | Issue: 12 | Pages: 1734-1742

10.1089/thy.2019.0256 | PMID 31680654 Get It

Background: Levothyroxine (LT4) is the mainstay of therapy for hypothyroidism. Yet, despite physician efforts at dose titration, some patients remain hypothyroid on LT4 doses in excess of weight-based calculations, a condition known as refractory hypothyroidism. The LT4 absorption test (LT4AT) has been proposed to have utility in these patients by enabling distinction of LT4 malabsorption from pseudomalabsorption, a condition of intentional nonadherence. Given its rare use in clinical practice, we reviewed our institution's experience with the LT4AT to assess its impact on management of refractory hypothyroidism. Methods: We reviewed the charts of 16 patients diagnosed with refractory hypothyroidism and who had completed the LT4AT between January 2015 to January 2019. The primary aim was to determine the utility of this test in distinguishing LT4 malabsorption from pseudomalabsorption. Secondary aims were to determine whether the results of this test impacted physicians' management decisions, as well as to report on clinical outcomes at follow-up. Our LT4AT is a six-hour test wherein patients receive a weight-based dose of LT4 followed by serial measurements of total thyroxine (TT4) and thyrotropin (TSH). Percentage absorption is calculated using the following formula, with normal absorption being ≥60%: Results: Percentage absorption was calculated in 13 of 16 patients due to lack of TT4 data for 3 patients. Absorption was impaired in one patient (% absorbed = 0), who had known causes of malabsorption. The remaining 12 patients had normal absorption by hour 4 of the test (% absorption 60–158) in conjunction with upward TT4 trends. Clinical follow-up ranged from 1 to 32 months (median 6.5 months), with 11 patients having follow-up data. Six of these had normal or suppressed TSH values at most recent follow-up, and four had improved but persistent TSH elevations. The one said patient with malabsorption improved with intravenous LT4. Conclusions: The LT4AT can provide valuable information for distinguishing malabsorption from pseudomalabsorption. Our findings support the combined use of calculated percentage absorptions with TT4 trends for at least a four-hour time frame when making determinations regarding absorption.
Tolerogenic Vaccination For Graves’ Disease — Targeting the Root of the Problem
Banga, JP, Stan, Marius N.

Mayo Clinic

Clinical Thyroidology | September 13, 2019 | Volume: 31 | Issue: 9 | Pages: 372-375

10.1089/ct.2019;31.372-375 Get It

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial
Kahaly, George J. , Stan, Marius N. , Frommer, Lara, Amer, Ahmed , Schuhmann, Imelda , Espié, Pascal, Rush, James S. , Basson, Craig T. , He, Yanling , Stan, Marius Nicolae, Stan, Marius N , Gergely, Péter Attila , Colin, Laurence , Amer, Ahmed

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 12, 2019 | Volume: 105 | Issue: 3 | Pages: 696-704

10.1210/clinem/dgz013 | PMID 31512728 Get It

Abstract Context The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell activation. Objective Evaluate efficacy and safety of a human, blocking, nondepleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD. Design Open-label, phase II proof-of-concept study. Setting Multicenter. Patients Fifteen with GD. Intervention Patients received 5 doses of iscalimab at 10 mg/kg intravenously over 12 weeks. Main outcome measures Thyroid-related hormones and autoantibodies, plasma soluble CD40, free CD40 on B cells, soluble CXCL13, pharmacokinetics, and safety were assessed. Results The iscalimab intervention resulted in complete CD40 engagement for up to 20 weeks. A clinical response and biochemical euthyroidism was observed in 7 of 15 (47%) patients. Free and total triiodothyronine and thyroxine normalized in 7 patients who did not receive any rescue medication with antithyroid drugs (ATD), and 2/15 (13.3%) showed normal thyrotropin. Six (40%) patients required ATD. Four of 7 responders relapsed after treatment completion. Serum concentrations of thyrotropin receptor autoantibodies (TSH-R-Ab) significantly declined in all patients (mean 15.3 IU/L vs 4.0 IU/L, 66% reduction; P < 0.001) and TSH-R-Ab levels normalized in 4 (27%). Thyroperoxidase and thyroglobulin autoantibodies significantly decreased in responders. Iscalimab rapidly reduced serum CXCL13 concentrations (P < 0.001). Twelve (80.0%) patients reported at least 1 adverse event (AE). All treatment-related AE were mild or moderate and resolved by end of the study. Conclusion Iscalimab was generally safe and clinically effective in a subgroup of hyperthyroid GD patients. The potential therapeutic benefit of iscalimab should be further tested.
A Novel Anti-Cd40 Monoclonal Antibody, Iscalimab, for Control of Graves’ Hyperthyroidism – A Proof-Of-Concept Trial
Kahaly, George J. , Frommer, Lara, Amer, Ahmed , Schuhmann, Imelda , Espié, Pascal, Rush, James S. , Basson, Craig T. , He, Y L , Stan, Marius N. , Gergely, Péter Attila , Colin, Laurence , Amer, A

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 12, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/jcem/dgz013 Get It

Abstract Context The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves’ disease (GD) by promoting auto-reactive B cell activation. Objective Evaluate efficacy and safety of a human, blocking, non-depleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD Design Open label, phase II proof-of-concept study Setting Multicenter Patients Fifteen with GD Intervention Patients received five doses of iscalimab at 10 mg/kg intravenously over 12 weeks. Main outcome measures Thyroid-related hormones and autoantibodies, plasma soluble CD40, free CD40 on B cells, soluble CXCL13, pharmacokinetics, and safety were assessed. Results The iscalimab intervention resulted in complete CD40 engagement for up to 20 weeks. A clinical response and biochemical euthyroidism was observed in seven of 15 (47%) patients. Free and total T3 and T4 normalized in seven patients who did not receive any rescue medication with anti-thyroid drugs (ATD), and 2/15 (13.3%) showed normal TSH. Six (40%) patients required ATD. Four of seven responders relapsed after treatment completion. Serum concentrations of thyrotropin receptor autoantibodies (TSH-R-Ab) significantly declined in all patients (mean 15.3 IU/L versus 4.0 IU/L, 66% reduction, P<0.001) and TSH-R-Ab levels normalized in four (27%). Thyroperoxidase and thyroglobulin autoantibodies significantly decreased in responders. Iscalimab rapidly reduced serum CXCL13 concentrations (P<0.001). Twelve (80.0%) patients reported at least one adverse event (AE). All treatment-related AE were mild or moderate and resolved by end of the study. Conclusion Iscalimab was generally safe and clinically effective in a subgroup of hyperthyroid GD patients. The potential therapeutic benefit of Iscalimab should be further tested.
Modulating the TSH Receptor with High Specificity Gets a Step Closer Toward Use in Clinical Practice
Banga, J. Paul, Stan, Marius N.

Mayo Clinic

Clinical Thyroidology | July 10, 2019 | Volume: 31 | Issue: 7 | Pages: 295-298

10.1089/ct.2019;31.295-298 Get It